Search results
Showing 226 to 240 of 264 results for carcinoma
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
This guidance has been updated and replaced by NICE technology appraisal guidance 1120.
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)
This guidance has been updated and replaced by NICE technology appraisal guidance 780.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)
Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.
This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS17Show all sections
Sections for QS17
NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
This guidance has been updated and replaced by NICE technology appraisal guidance 849.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
This guidance has been updated and replaced by NICE technology appraisal guidance 432.
Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for HTG439Show all sections